share_log

BioVie | SC 13G: Statement of acquisition of beneficial ownership by individuals-3i, LP(7.6%),3i Management LLC(7.6%), etc.

BioVie | SC 13G: Statement of acquisition of beneficial ownership by individuals-3i, LP(7.6%),3i Management LLC(7.6%), etc.

BioVie | SC 13G：超過5%持股股東披露文件-3i, LP(7.6%),3i Management LLC(7.6%)等
美股SEC公告 ·  2024/10/25 16:03

Moomoo AI 已提取核心訊息

On October 22, 2024, a Schedule 13G filing was made with the U.S. Securities and Exchange Commission by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively reporting a shared voting and dispositive power over 1,260,000 shares of BioVie Inc.'s Class A common stock. This stake represents 7.6% of the company's issued shares, based on the 16,612,374 shares outstanding as reported in BioVie's prospectus supplement dated October 23, 2024. The filing indicates that the shares are beneficially owned by 3i, LP and that 3i Management LLC, as the general partner and manager of 3i, LP, along with Maier Joshua Tarlow, as the manager of 3i Management LLC, have shared power to vote and dispose of the shares. The reporting persons have entered into a Joint Filing Agreement, indicating that they will file jointly for any subsequent amendments. The filing emphasizes that the acquisition of the shares is not for the purpose of changing or influencing the control of BioVie Inc. and is not connected with any transaction with such purpose or effect.
On October 22, 2024, a Schedule 13G filing was made with the U.S. Securities and Exchange Commission by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively reporting a shared voting and dispositive power over 1,260,000 shares of BioVie Inc.'s Class A common stock. This stake represents 7.6% of the company's issued shares, based on the 16,612,374 shares outstanding as reported in BioVie's prospectus supplement dated October 23, 2024. The filing indicates that the shares are beneficially owned by 3i, LP and that 3i Management LLC, as the general partner and manager of 3i, LP, along with Maier Joshua Tarlow, as the manager of 3i Management LLC, have shared power to vote and dispose of the shares. The reporting persons have entered into a Joint Filing Agreement, indicating that they will file jointly for any subsequent amendments. The filing emphasizes that the acquisition of the shares is not for the purpose of changing or influencing the control of BioVie Inc. and is not connected with any transaction with such purpose or effect.
2024年10月22日，3i有限合夥企業、3i管理有限責任公司和Maier Joshua Tarlow向美國證券交易委員會提交了一份13G表格，共同報告對biovie股份公司的126萬股A類普通股享有共同的投票權和處分權。根據biovie於2024年10月23日的招股說明書披露，這一股權佔公司發行股份的7.6%，基數爲16,612,374股。該報告顯示，這些股份由3i有限合夥企業實際擁有，並且3i管理有限責任公司作爲3i有限合夥企業的普通合夥人和管理人，以及Maier Joshua Tarlow作爲3i管理有限責任公司的管理人，共同具有對這些股份的投票和處分權。報告人已簽署聯合申報協議，表示他們將聯合提交任何後續修訂。提交強調，收購這些股份並非旨在改變或影響對biovie股份公司的控制，也與此類目的或效果的交易無關。
2024年10月22日，3i有限合夥企業、3i管理有限責任公司和Maier Joshua Tarlow向美國證券交易委員會提交了一份13G表格，共同報告對biovie股份公司的126萬股A類普通股享有共同的投票權和處分權。根據biovie於2024年10月23日的招股說明書披露，這一股權佔公司發行股份的7.6%，基數爲16,612,374股。該報告顯示，這些股份由3i有限合夥企業實際擁有，並且3i管理有限責任公司作爲3i有限合夥企業的普通合夥人和管理人，以及Maier Joshua Tarlow作爲3i管理有限責任公司的管理人，共同具有對這些股份的投票和處分權。報告人已簽署聯合申報協議，表示他們將聯合提交任何後續修訂。提交強調，收購這些股份並非旨在改變或影響對biovie股份公司的控制，也與此類目的或效果的交易無關。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    ImmunoPrecise Antibodies
    IPA
    -- 0.790
    Metagenomi Technologies, LLC
    MGX
    -- 3.970
    Nutriband
    NTRB
    -- 6.960
    Seres Therapeutics
    MCRB
    -- 0.918
    Absci Corp
    ABSI
    -- 4.035
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    中美談話新契機，通脹不再？
    🎙️討論： 1. 特朗普上台後，對華政策如何影響中國資產？ 2. 美股市場通脹風險下降，哪些板塊受益？ 展开
    中國將在明年採取 “適度寬鬆” 的貨幣政策，這是自2011年以來首次轉向寬鬆